Lv11
50 积分 2024-07-02 加入
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
3个月前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
3个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
3个月前
已完结
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
3个月前
已完结
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
3个月前
已完结
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
3个月前
已完结
Shifting Tides Offer New Hope For Obesity
3个月前
已完结
Why does GLP ‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP ‐1 agonist alone in obese adults without type 2 diabetes?
3个月前
已完结
Glucagon, from past to present: a century of intensive research and controversies
3个月前
已完结
Differential regulation of histamine H1 receptor-mediated ERK phosphorylation by Gq proteins and arrestins
7个月前
已完结
皖公网安备34019202002308
